ACT Brief: RBQM Analysis Frequency, Building Trust in Oncology Data, and Rare Pediatric PRV Monetization

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In her October column, Sylviane de Viron examined why real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis. Signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration, so data availability, analysis frequency, and team review capacity should move at different speeds by design rather than all moving at once.
• In part one of a new video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation is what makes reliable real-world evidence generation in oncology possible. Source lineage, standardization, and reconciliation are not optional workflow steps but foundational requirements when evidence will later be used to support regulatory submissions and clinical decision-making across fragmented health systems.
• Ultragenyx entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for 210 million dollars, earned upon FDA approval of Genglycos for glycogen storage disease type Ia. The sale provides non-dilutive capital for future rare disease development and illustrates a cycle the company has repeated: Genglycos itself was funded by capital from an earlier voucher sale, and the voucher earned through its approval is now funding the next generation of therapies.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.